Supernus Pharmaceuticals, Inc. · NASDAQ:SUPN

Supernus Pharmaceuticals — Corporate Update (October 2016)

12 slides from Supernus Pharmaceuticals's corporate update, Oct 11, 2016

  1. Slide 1: SPN-812 Phase IIb Topline Data

    Supernus Pharmaceuticals SPN-812 Phase IIb Topline Data Investor Webcast – October 11, 2016 © 2016 Supernus Pharmaceuticals, Inc. All Rights Reserved. 1

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the meaning of the federal securities laws. These statements, among other things, relate to Supernus’ business strategy, goals and expec

  3. Slide 3: SPN-812: Novel Non-Stimulant ADHD Product

    SPN-812: Novel Non-Stimulant ADHD Product Viloxazine hydrochloride ‒ Norepinephrine reuptake inhibitor Once-daily oral extended-release product New Chemical Entity (NCE) ‒ Five year market exclusivity ‒ Previously marketed outside the US as an antidepressant Building strong IP portfolio with expirat

  4. Slide 4: SPN-812 Phase IIb Design: Objectives and Endpoints

    SPN-812 Phase IIb Design Objectives: ‒ Assess effect of SPN-812 ER in reducing symptoms of ADHD in children aged 6-12 years ‒ Evaluate safety and tolerability of SPN-812 ER in children with ADHD Primary Endpoint: ‒ Change from baseline to End of Study in the ADHD-RS-IV total score Secondary Endpoint

  5. Slide 5: SPN-812 Phase IIb Design

    SPN-812 Phase IIb Design Design: ‒ Double-blind, placebo-controlled, multicenter ‒ Dose-ranging study; 5-arm, parallel-group ‒ Monotherapy Randomization: ‒ Randomized in a ratio of 1:2 of placebo to each of the active treatment arms (100/200/300/400 mg) ‒ 222 subjects randomized Study Duration: ‒ 3

  6. Slide 6: Three SPN-812 Doses Met Primary Endpoint

    Three SPN-812 Doses Met Primary Endpoint Primary Analysis Change from baseline in ADHD-RS-IV Total Score (ITT Population with LOCF) 400 mg 300 mg 200 mg 100 mg Placebo Statistics N=44 N=47 N=46 N=45 N=24 LS Mean -19.0 -18.6 -18.4 -16.7 -10.5 End of Effect Size 0.63 0.60 0.55 0.46 Study P-value 0.021

  7. Slide 7: LS Means of Change from Baseline in ADHD-RS-IV Score

    LS Means of Change from Baseline in ADHD-RS-IV Score SPN-812 ER SPN-812 ER SPN-812 ER SPN-812 ER Placebo 100 mg 200 mg 300 mg 400 mg 0.0 -2.0 -4.0 -6.0 -8.0 -10.0 -12.0 -10.5 -14.0 -16.0 -18.0 -16.7 -20.0 -18.4 * -18.6 * * -19.0 *P-value <0.05 © 2016 Supernus Pharmaceuticals, Inc. All Rights Reserve

  8. Slide 8: All SPN-812 Doses Met Primary Endpoint

    All SPN-812 Doses Met Primary Endpoint Sensitivity Analysis Change from baseline in ADHD-RS-IV Total Score (PP Population) 400 mg 300 mg 200 mg 100 mg Placebo Statistics N=32 N=34 N=29 N=35 N=19 LS Mean -23.3 -19.2 -20.7 -18.3 -9.4 End of P-value 0.001* 0.017* 0.008* 0.028* Study * At end of study,

  9. Slide 9: Three SPN-812 Doses Met CGI-S Secondary Endpoint

    Three SPN-812 Doses Met CGI-S Secondary Endpoint Analysis of Secondary Endpoints, CGl-I and CGI-S (ITT Population with LOCF) 400 mg 300 mg 200 mg 100 mg Placebo Statistics N=44 N=47 N=46 N=45 N=24 Change from baseline to End of Study in CGI-S LS Mean -1.7 -1.6 -1.5 -1.4 -0.8 P-value 0.014* 0.015* 0.

  10. Slide 10: SPN-812 Was Well Tolerated

    SPN-812 Was Well Tolerated Percentage of Patients with Related AEs, >5% SPN-812 ER Placebo 100 mg 200 mg 300 mg 400 mg Adverse Event (AE) N=24 N=48 N=48 N=48 N=49 Somnolence 0 14.6 20.8 20.8 24.5 Decreased appetite 8.3 10.4 12.5 8.3 16.3 Headache 0 4.2 10.4 6.3 12.2 Insomnia 0 6.3 4.2 6.3 6.3 Nausea

  11. Slide 11: SPN-812: Novel Non-Stimulant ADHD Product

    SPN-812: Novel Non-Stimulant ADHD Product Total ADHD Prescriptions Market Opportunity 8% $2.5B Stimulant Non- Stimulant Completed Phase IIa and 92% Phase IIb studies in ADHD Demonstrated safety and 8 efficacy in adults and 6 ADHD children 4 Millions Prevalence 2 2017 Phase III studies 0 Age 6-17 Age

  12. Slide 12: Positioned For Continued Strong Growth

    Positioned For Continued Strong Growth Strong Portfolio in Neurology Potential Peak Sales for Oxtellar XR® and Trokendi XR® >$500M Innovative Late Stage Portfolio in Psychiatry SPN-812 : Highly Effective and Well Tolerated Non-Stimulant SPN-810 : The First Treatment for Impulsive Aggression © 2016 S

Supernus Pharmaceuticals — Corporate Update (October 2016) on 6ix